Skip to main content
SpringerLink
Log in

Gastric Toxicity of Antiplatelet Therapy with Low-Dose Aspirin

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Low-dose aspirin is widely employed as antiplatelet therapy for cardiovascular disorders. However, even in the dosages usually employed for that purpose (75 to 325mg daily), the drug maintains its ability to damage the gastric mucosa by inducing bleeding ulcers and/or erosions. Pharmacological protection is therefore necessary. Specific long term studies with histamine H2 receptor antagonists or sucralfate are lacking, but data from trials on the prevention of gastric damage by other nonsteroidal anti-inflammatory drugs (NSAIDs) are discouraging. Recent preliminary data suggest that misoprostol, in keeping with its ability to protect both gastric and duodenal mucosa from long term NSAID treatment, seems to be effective also against long term low-dose aspirin therapy in this setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320–31

    Article  Google Scholar 

  2. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991; 266: 521–7

    Article  PubMed  CAS  Google Scholar 

  3. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287–94

    Article  PubMed  CAS  Google Scholar 

  4. Kurata JH, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalization. J Clin Gastroenterol 1990; 12: 260–6

    Article  PubMed  CAS  Google Scholar 

  5. Laporte JR, Carne X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991; 337: 85–9

    Article  PubMed  CAS  Google Scholar 

  6. Levy M, Miller DR, Kaufman DW, et al. Major upper gastrointestinal tract bleeding: relation to use of aspirin and other nonnarcotic analgesics. Arch Intern Med 1988; 148: 281–5

    Article  PubMed  CAS  Google Scholar 

  7. Steering Committee of Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–35

    Article  Google Scholar 

  8. Slattery J, Warlow CP, Shorrock CJ, et al. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin — analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37: 509–11

    Article  PubMed  CAS  Google Scholar 

  9. Weil J, Colin-Jones D, Langman MJS, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827–30

    Article  PubMed  CAS  Google Scholar 

  10. Kaufman DW, Kelly JP, Sheehan JE, et al. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993; 53: 485–94

    Article  PubMed  CAS  Google Scholar 

  11. Silagy CA, Mc Neil JJ, Donnan GA, et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993; 54: 84–9

    Article  PubMed  CAS  Google Scholar 

  12. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261–6

    Article  Google Scholar 

  13. Stalnikowicz-Darvasi R. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis. J Clin Gastroenterol 1995; 21: 13–6

    Article  PubMed  CAS  Google Scholar 

  14. Lee M, Cruer B, Feldman M. Dose effects of aspirin and gastric prostaglandins and stomach mucosal injury. Ann Intern Med 1994; 120: 184–9

    PubMed  CAS  Google Scholar 

  15. Guslandi M. NSAID gastropathy. In: Guslandi M, Braga PC, editors. Drug-induced injury to the digestive system. Heidelberg, Berlin: Springer-Verlag, 1993: 19–31

    Chapter  Google Scholar 

  16. Zandomeneghi R, Serra L, Pavesi C, et al. Effects of aspirin and indomethacin on epidermal growth factor secretion in duodenal tissue fragments cultivated in vitro. Digestion 1992; 51: 37–41

    Article  PubMed  CAS  Google Scholar 

  17. Lee M, Aldred K, Lee E, Feldman M. Aspirin-induced acute gastric mucosal injury is a neutrophil-independent process in rats. Am J Physiol 1992; 263: G920–6

    PubMed  CAS  Google Scholar 

  18. Pihan G, Regillo C, Szabo S. Free radicals and lipid peroxidation in ethanol- and aspirin-induced gastric mucosal injury. Dig Dis Sci 1987; 32: 1395–401

    Article  PubMed  CAS  Google Scholar 

  19. Graham DY, Lacey Smith J, Spjut HJ, et al. Gastric adaptation: studies in humans during continuous aspirin administration. Gastroenterology 1988; 95: 327–33

    PubMed  CAS  Google Scholar 

  20. Konturek JW, Dembinski A, Stoll R, et al. Mucosal adaptation to aspirin-induced gastric damage in humans: studies on blood flow, gastric mucosal growth and neutrophil activation. Gut 1994; 35: 1197–204

    Article  PubMed  CAS  Google Scholar 

  21. Savon JJ, Allen ML, Di Marino AJ, et al. Gastrointestinal blood loss with low dose (325mg) plain and enteric-coated aspirin administration. Am J Gastroenterol 1995; 90: 581–5

    PubMed  CAS  Google Scholar 

  22. Petroski D. Gastrointestinal blood loss with low-dose aspirin. Am J Gastroenterol 1995; 90: 2071

    PubMed  CAS  Google Scholar 

  23. Caruso I, Bianchi Porro G. Gastroscopic evaluation of anti-inflammatory agents. BMJ 1980; 280: 75–8

    Article  PubMed  CAS  Google Scholar 

  24. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241–9

    PubMed  CAS  Google Scholar 

  25. Simon B, Dammann HG, Muller P. Stomach tolerance of buffered and unbuffered low-dose acetylsalicylic acid: an endoscopic controlled double-blind study in volunteers. Z Gastroenterol 1990; 28: 137–8

    PubMed  CAS  Google Scholar 

  26. Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 1993; 15: 314–20

    PubMed  CAS  Google Scholar 

  27. Hoftiezer JW, Burks M, Silvoso GR, et al. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet 1980; I: 609–12

    Article  Google Scholar 

  28. Petroski D. A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies. Am J Gastroenterol 1986; 81: 26–8

    PubMed  CAS  Google Scholar 

  29. Jaszewski R. Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal antiinflammatory drug therapy. J Clin Gastroenterol 1990; 12: 10–2

    Article  PubMed  CAS  Google Scholar 

  30. Savon JJ, Allen ML, Di Marino AJ, et al. Gastrointestinal blood loss with low dose (350mg) plain and enteric-coated aspirin administration. Am J Gastroenterol 1995; 90: 581–5

    PubMed  CAS  Google Scholar 

  31. French PC, Darekar BS, Mills JG, et al. Ranitidine in the prevention of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulceration in arthritic patients. Eur J Gastroenterol Hepatol 1994; 6: 1141–7

    Article  Google Scholar 

  32. Lanza F, Peace K, Gustitus L, et al. A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol 1988; 83: 143–6

    PubMed  CAS  Google Scholar 

  33. Agrawal NW, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991; 115: 195–200

    PubMed  CAS  Google Scholar 

  34. Silverstein FE, Kimmey MB, Saunders DR, et al. Gastric protection by misoprostol against 1300 mg of aspirin: an endoscopic study. Dig Dis Sci 1986; 31: 127S–41S

    Article  Google Scholar 

  35. Jiranek GC, Kimmey BM, Saunders DR, et al. Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study. Gastroenterology 1989; 96: 656–61

    PubMed  CAS  Google Scholar 

  36. Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind multicenter study. Am J Gastroenterol 1996; 91: 223–7

    PubMed  CAS  Google Scholar 

  37. Valentini M, Cannizzaro R, Poletti M, et al. Non-steroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. J Clin Oncol 1995; 13: 2637–42

    PubMed  CAS  Google Scholar 

  38. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344–50

    PubMed  CAS  Google Scholar 

  39. Goddard AF, Donnelly MT, Filipowicz B, et al. Low-dose misoprostol as prophylaxis against low-dose aspirin-induced gastroduodenal mucosal injury [abstract]. Gut 1996; 39 Suppl. 1: A33

    Google Scholar 

  40. Bardhan KD, Bjarnason I, Scott DL, et al. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol 1993; 32: 990–5

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Unit, S Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy

    Mario Guslandi

Authors
  1. Mario Guslandi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guslandi, M. Gastric Toxicity of Antiplatelet Therapy with Low-Dose Aspirin. Drugs 53, 1–5 (1997). https://doi.org/10.2165/00003495-199753010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199753010-00001

Search

Navigation